Electra lights up with $350M IPO for pivotal immune-disease drug development
Electra Therapeutics raised $350M in an upsized IPO to fund pivotal development of its immune-disease drug.
Electra Therapeutics
Private
Clinical-stage biotechnology company developing novel antibody therapeutics for inflammatory and immune disorders.
Company Info
Sector:Antibodies
Headquarters:South San Francisco, CA, USA
Founded:2017
Website:electra-therapeutics.com/
Recent News
Electra amasses $350M in biotech's latest big IPO
Rare disease drugmaker Electra Therapeutics banked $350 million in an initial public offering, becoming the 21st biotechnology company to price a new stock issuance in 2026.
Electra seeks $342M IPO to power inflammatory drug’s ph. 3 push
News from Fierce Biotech: Electra seeks $342M IPO to power inflammatory drug’s ph. 3 push
Electra's Upsized IPO Lands $350M for New Class of Precision Immunology Drugs
Electra's Upsized IPO Lands $350M for New Class of Precision Immunology Drugs